Algazi A, Tsai K, Bannavong D, et al. Clinical immune monitoring and biomarker data of pIL-12 monotherapy compared to pIL-12 with pembrolizumab in metastatic melanoma supports the rationale for combination therapy. SMR 2017, abstract FC05-3.
80-plussers profiteren minder van nieuwe kankerbehandelingen
jan 2026 | Borstkanker, Dermato-oncologie, Longoncologie, Maag-darm-leveroncologie, Ouderen, Uro-oncologie